This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2018 Nov 6;6(Suppl 1):115.

doi: 10.1186/s40425-018-0423-x.

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) : Washington, D.C., USA. 7-11 November 2018

No authors listed

PMID: 30400822
PMCID: PMC6220479
DOI: 10.1186/s40425-018-0423-x

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) : Washington, D.C., USA. 7-11 November 2018

No authors listed. J Immunother Cancer. 2018.

. 2018 Nov 6;6(Suppl 1):115.

doi: 10.1186/s40425-018-0423-x.

PMID: 30400822
PMCID: PMC6220479
DOI: 10.1186/s40425-018-0423-x

Erratum in

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018).
Berry S, Giraldo N, Nguyen P, Green B, Xu H, Ogurtsova A, Soni A, Succaria F, Wang D, Roberts C, Stein J, Engle E, Pardoll D, Anders R, Cottrell T, Taube JM, Tran B, Voskoboynik M, Kuo J, Bang YL, Chung HC, Ahn MJ, Kim SW, Perera A, Freeman D, Achour I, Faggioni R, Xiao F, Ferte C, Lemech C, Meric-Bernstam F, Werner T, Hodi S, Messersmith W, Lewis N, Talluto C, Dostalek M, Tao A, McWhirter S, Trujillo D, Luke J, Xu C, BoMarelli, Qi J, Qin G, Yu H, Jenkins M, Lo KM, Halle JP, Lan Y, Taylor M, Vogelzang N, Cohn A, Stepan D, Shumaker R, Dutcus C, Guo M, Schmidt E, Rasco D, Brose M, Vogelzang N, Di Simone C, Jain S, Richards D, Encarnacion C, Rasco D, Shumaker R, Dutcus C, Stepan D, Guo M, Schmidt E, Taylor M, Vogelzang N, Encarnacion C, Cohn A, Di Simone C, Rasco D, Richards D, Taylor M, Dutcus C, Stepan D, Shumaker R, Guo M, Schmidt E, Mier J, An J, Yang YY, Lee WH, Yang J, Kim JK, Kim HG, Paek SH, Lee JW, Woo J, Kim JB, Kwon H, Lim W, Paik NS, Kim YK, Moon BI, Janku F, Tan D, Martin-Liberal J, Takahashi S, Geva R, Gucalp A, Chen X, Subramanian K, Mataraza J, Wheler J, Bedard P. Berry S, et al. J Immunother Cancer. 2019 Feb 13;7(1):46. doi: 10.1186/s40425-019-0519-y. J Immunother Cancer. 2019. PMID: 30760319 Free PMC article.

No abstract available

PubMed Disclaimer

Figures

Fig. 1 (abstract P400). — Fig. 1 (abstract P400).
See text for description

Fig. 1 (abstract P424). — Fig. 1 (abstract P424).
NKTR-214 mediated intratumoral Treg depletion

Fig. 1 (abstract P426). — Fig. 1 (abstract P426).
See text for description

Fig. 1 (abstract P427). — Fig. 1 (abstract P427).
Orthotopic survival and immune sensitivities

Fig. 2 (abstract P427). — Fig. 2 (abstract P427).
PD-L1 expression on myeloid cells in QPP8 TME

Fig. 1 (abstract P430). — Fig. 1 (abstract P430).
See text for description

Fig. 2 (abstract P430). — Fig. 2 (abstract P430).
See text for description

Fig. 3 (abstract P430). — Fig. 3 (abstract P430).
See text for description

Fig. 1 (abstract P431). — Fig. 1 (abstract P431).
See text for description

Fig. 2 (abstract P431). — Fig. 2 (abstract P431).
See text for description

Fig. 3 (abstract P431). — Fig. 3 (abstract P431).
See text for description

Fig. 1 (abstract P432). — Fig. 1 (abstract P432).
See text for description

Fig. 2 (abstract P432). — Fig. 2 (abstract P432).
See text for description

Fig. 3 (abstract P432). — Fig. 3 (abstract P432).
See text for description

Fig. 4 (abstract P432). — Fig. 4 (abstract P432).
See text for description

Fig. 1 (abstract P433). — Fig. 1 (abstract P433).
See text for description

Fig. 1 (abstract P434). — Fig. 1 (abstract P434).
Mathematical modeling frameworks developed

Fig. 2 (abstract P434). — Fig. 2 (abstract P434).
Heatmaps indicating the number of cancer cells

Fig. 1 (abstract P437). — Fig. 1 (abstract P437).
See text for description

Fig. 2 (abstract P437). — Fig. 2 (abstract P437).
See text for description

Fig. 1 (abstract P442). — Fig. 1 (abstract P442).
See text for description

Fig. 1 (abstract P456). — Fig. 1 (abstract P456).
See text for description

Fig. 2 (abstract P456). — Fig. 2 (abstract P456).
See text for description

Fig. 1 (abstract P457). — Fig. 1 (abstract P457).
See text for description

Fig. 2 (abstract P457). — Fig. 2 (abstract P457).
See text for description

Fig. 3 (abstract P457). — Fig. 3 (abstract P457).
See text for description

Fig. 1 (abstract P458). — Fig. 1 (abstract P458).
See text for description

Fig. 1 (abstract P464). — Fig. 1 (abstract P464).
Treating mice with 1 large, 1 small and disseminated COLD B78/B16 tumors

Fig. 2 (abstract P464). — Fig. 2 (abstract P464).
See text for description

Fig. 1 (abstract P465). — Fig. 1 (abstract P465).
Peripheral Blood Immunocyte Response during CRT

Fig. 2 (abstract P465). — Fig. 2 (abstract P465).
Changes in Immune Checkpoint Expression

Fig. 3 (abstract P465). — Fig. 3 (abstract P465).
The Effect on Memory T-cell Response

Fig. 1 (abstract P468). — Fig. 1 (abstract P468).
See text for description

Fig. 1 (abstract P489). — Fig. 1 (abstract P489).
See text for description

Fig. 2 (abstract P489). — Fig. 2 (abstract P489).
See text for description

Fig. 3 (abstract P489). — Fig. 3 (abstract P489).
See text for description

Fig. 4 (abstract P489). — Fig. 4 (abstract P489).
See text for description

Fig. 5 (abstract P489). — Fig. 5 (abstract P489).
See text for description

Fig. 6 (abstract P489). — Fig. 6 (abstract P489).
See text for description

Fig. 1 (abstract P491). — Fig. 1 (abstract P491).
See text for description

Fig. 2 (abstract P491). — Fig. 2 (abstract P491).
See text for description

Fig. 3 (abstract P491). — Fig. 3 (abstract P491).
See text for description

Fig. 1 (abstract P498). — Fig. 1 (abstract P498).
Tumors derived Kras-p53 mice highly desmoplastic

Fig. 2 (abstract P498). — Fig. 2 (abstract P498).
Kras-P53 tumors increased inflammatory leukocytes

Fig. 1 (abstract P506). — Fig. 1 (abstract P506).
See text for description

Fig. 2 (abstract P506). — Fig. 2 (abstract P506).
See text for description

Fig. 3 (abstract P506). — Fig. 3 (abstract P506).
See text for description

Fig. 1 (abstract P507). — Fig. 1 (abstract P507).
See text for description

Fig. 2 (abstract P507). — Fig. 2 (abstract P507).
See text for description

Fig. 1 (abstract P526). — Fig. 1 (abstract P526).
See text for description

Fig. 2 (abstract P526). — Fig. 2 (abstract P526).
See text for description

Fig. 3 (abstract P526). — Fig. 3 (abstract P526).
See text for description

Fig. 4 (abstract P526). — Fig. 4 (abstract P526).
See text for description

Fig. 5 (abstract P526). — Fig. 5 (abstract P526).
See text for description

Fig. 1 (abstract P531). — Fig. 1 (abstract P531).
See text for description

Fig. 1 (abstract P533). — Fig. 1 (abstract P533).
Included patients

Fig. 1 (abstract P536). — Fig. 1 (abstract P536).
The recurrence rate of immune-mediated diarrhea (IMD) after ICPI resumption according to the immunosuppression (IS) requirement for the initial immune-mediated diarrhea

Fig. 2 (abstract P536). — Fig. 2 (abstract P536).
The reccurence immune-mediated diarrhea after ICPI resumption by the type of ICPI

Fig. 1 (abstract P537). — Fig. 1 (abstract P537).
Kaplan-Meier overall survival curve stratified by immune checkpoint inhibitor (ICPI)-induced diarrhea/colitis status

Fig. 2 (abstract P537). — Fig. 2 (abstract P537).
Kaplan-Meier progression-free survival curve stratified by immune checkpoint inhibitor (ICPI)-induced diarrhea/colitis status

Fig. 3 (abstract P537). — Fig. 3 (abstract P537).
Kaplan-Meier overall survival curve stratified by diarrhea grade

Fig. 1 (abstract P538). — Fig. 1 (abstract P538).
Decrease in calprotectin values after vedolizumab/infliximab therapy according to time from onset to treatment initiation

Fig. 1 (abstract P543). — Fig. 1 (abstract P543).
See text for description

Fig. 1 (abstract P544). — Fig. 1 (abstract P544).
See text for description

Fig. 2 (abstract P544). — Fig. 2 (abstract P544).
See text for description

Fig. 3 (abstract P544). — Fig. 3 (abstract P544).
See text for description

Fig. 4 (abstract P544). — Fig. 4 (abstract P544).
See text for description

Fig. 1 (abstract P547). — Fig. 1 (abstract P547).
See text for description

Fig. 2 (abstract P547). — Fig. 2 (abstract P547).
See text for description

Fig. 1 (abstract P563). — Fig. 1 (abstract P563).
Dependence of Grade 3&4 AEs upon ICI drug exposure

Fig. 1 (abstract P564). — Fig. 1 (abstract P564).
See text for description

Fig. 1 (abstract P567). — Fig. 1 (abstract P567).
Incidence of Grade 3-5 Adverse Events Ipilimumab

Fig. 2 (abstract P567). — Fig. 2 (abstract P567).
Incidence of Grade 3-5 Adverse Events Atezolizumab

Fig. 3 (abstract P567). — Fig. 3 (abstract P567).
Incidence of Grade 3-5 Adverse Events Nivolumab

Fig. 4 (abstract P567). — Fig. 4 (abstract P567).
Incidence of Grade 3-5 Adverse Events Pembrolizumab

Fig. 1 (abstract P569). — Fig. 1 (abstract P569).
See text for description

Fig. 2 (abstract P569). — Fig. 2 (abstract P569).
See text for description

Fig. 3 (abstract P569). — Fig. 3 (abstract P569).
See text for description

Fig. 4 (abstract P569). — Fig. 4 (abstract P569).
See text for description

Fig. 5 (abstract P569). — Fig. 5 (abstract P569).
See text for description

Fig. 6 (abstract P569). — Fig. 6 (abstract P569).
See text for description

Fig. 7 (abstract P569). — Fig. 7 (abstract P569).
See text for description

Fig. 1 (abstract P579). — Fig. 1 (abstract P579).
Chemerin upregulates PTEN decreases PD-L1 via CMKLR1

Fig. 2 (abstract P579). — Fig. 2 (abstract P579).
Chemerin diminishes tumor cell invasion via CMKLR1

Fig. 3 (abstract P579). — Fig. 3 (abstract P579).
Cytotoxicity increased chemerin-treated tumor cells

Fig. 4 (abstract P579). — Fig. 4 (abstract P579).
Chemerin treatment comp PD-L1 siRNA & atezolizumab

Fig. 1 (abstract P582). — Fig. 1 (abstract P582).
Activated CD8 T-cell infiltration by ARID1A expression in NSCLC samples from TCGA^

Fig. 2 (abstract P582). — Fig. 2 (abstract P582).
mRNA expression of CD274 (PD-L1) by ARID1A expression in NSCLC samples from TCGA⁺

Fig. 1 (abstract P586). — Fig. 1 (abstract P586).
See text for description

Fig. 2 (abstract P586). — Fig. 2 (abstract P586).
See text for description

Fig. 1 (abstract P587). — Fig. 1 (abstract P587).
See text for description

Fig. 2 (abstract P587). — Fig. 2 (abstract P587).
See text for description

Fig. 3 (abstract P587). — Fig. 3 (abstract P587).
See text for description

Fig. 1 (abstract P588). — Fig. 1 (abstract P588).
AI-MHC

Fig. 2 (abstract P588). — Fig. 2 (abstract P588).
DeepMANA

Fig. 3 (abstract P588). — Fig. 3 (abstract P588).
DeepTCR

Fig. 1 (abstract P595). — Fig. 1 (abstract P595).
See text for description

Fig. 2 (abstract P595). — Fig. 2 (abstract P595).
See text for description

Fig. 1 (abstract P596). — Fig. 1 (abstract P596).
Gene Expression Signature

Fig. 2 (abstract P596). — Fig. 2 (abstract P596).
Gene Rank Score comparisons

Fig. 3 (abstract P596). — Fig. 3 (abstract P596).
PD-L1 gene expression

Fig. 1 (abstract P612). — Fig. 1 (abstract P612).
See text for description

Fig. 2 (abstract P612). — Fig. 2 (abstract P612).
See text for description

Fig. 1 (abstract P619). — Fig. 1 (abstract P619).
Intratumoral injection site

Fig. 1 (abstract P648). — Fig. 1 (abstract P648).
Effects of IL-12 on healthy T-cells

Fig. 2 (abstract P648). — Fig. 2 (abstract P648).
Different subsets of CD8+ cells classified

Fig. 3 (abstract P648). — Fig. 3 (abstract P648).
Effects of antibodies blocking different inhibitor

Fig. 1 (abstract P665). — Fig. 1 (abstract P665).
See text for description

Fig. 1 (abstract P692). — Fig. 1 (abstract P692).
See text for description

Fig. 1 (abstract P702). — Fig. 1 (abstract P702).
Trends in liver enzymes

Fig. 2 (abstract P702). — Fig. 2 (abstract P702).
Trends in additional liver biochemical tests

Fig. 3 (abstract P702). — Fig. 3 (abstract P702).
Liver biopsy histology

Fig. 1 (abstract P705). — Fig. 1 (abstract P705).
CD4 and CD8 T cells redistribute in the spleen. Animals were implanted for 14 days with B16 melanoma cells, after receiving 3 doses of anti-PD-L1 the CD8/CD4 T cell ratio increases

Fig. 2 (abstract P705). — Fig. 2 (abstract P705).
Splenic CD4 T cells show an activated phenotype. After tumor implant and antibody treatment, CD4 T cells show increased expression of CD25, CD69, CD278, and CD279. Similar results were observed in CD8 T cells (not shown)

Fig. 3 (abstract P705). — Fig. 3 (abstract P705).
CD8⁺ cells infiltrate the tumor and co-localize with CD11c^* cells. After tumor implant and antibody treatment, the tumors were excised and analyzed by fluorescent microscopy. Pictures were taken with a 40X objective

Fig. 4 (abstract P705). — Fig. 4 (abstract P705).
Cytokine and chemokine profile in serum. After tumor implant and antibody treatment, the analysis of the samples with LEGENDplex^TM show A) Increased Th Cytokines. B) Decreased pro-inflammatory cytokines. C) Increased chemokine production

Fig. 5 (abstract P705). — Fig. 5 (abstract P705).
A) Tumor-specific infiltrating CD8⁺ T cells increase 24 days after treatment. Animals were implanted with SIYRYYGL-expressing B16 cells and 24 days after treatment the tumor was collected and analyzed. B) Anti-PD-L1 treatment reduces tumor growth

Fig. 1 (abstract O6). — Fig. 1 (abstract O6).
See text for description

See this image and copyright information in PMC

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database